The FDA has encouraged companies to pursue nonprescription status for opioid-reversal drugs.
Source link
Tags: abuseAnalgesicsapprovalBankingBanking/CreditC&E Industry News FilterCommunityContent TypescorporateCorporate/Industrial NewscreditDevelopmentdrugDrug/Substance Use/AbuseEBSEmergent BiosolutionsFactiva FiltersFDAFinancial Servicesgeneral newsgovernment policyhealthcareHealthcare/Life SciencesheroinHeroin/Illegal Opioid Use/Abuseillegal opioid useindustrial newskwexclusivelife sciencesmedication abuseMedication Abuse/Misusemedicationsmisusenaloxonenew productNew Product/Service Testingnew productsNew Products/ServicesOver-the-counter DrugsOvertheCounterPharmaceuticalspoliticalPolitical/General NewsPrescription DrugsproductProduct/Service ApprovalsproductsProducts/ServicespursuesregulationRegulation/Government PolicyResearchResearch/DevelopmentSavings Institutionsservice approvalsservice testingservicesSocial IssuessocietySociety/Communityspecialized drugsSpecialized Drugs/MedicationsStartupsubstance useSwabSYNDWSJ-PRO-WSJ.comwsjhealth
